|
| | Publication Year | Title | Author(s) |
| 1 | Mar-2021 | Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. | Chia, Puey Ling ; Parakh, Sagun ; Russell, Prudence; Gan, Hui K ; Asadi, Khashayar ; Gebski, Val; Murone, Carmel ; Walkiewicz, Marzena; Liu, Zhanqi; Thapa, Bibhusal ; Scott, Fiona E; Scott, Andrew M ; John, Thomas |
| 162 | Dec-2020 | Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. | Chia, Puey Ling ; Russell, Prudence; Asadi, Khashi; Thapa, Bibhusal ; Gebski, Val; Murone, Carmel ; Walkiewicz, Marzena; Eriksson, Ulf; Scott, Andrew M ; John, Thomas |
| 163 | 2-Oct-2020 | Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. | Chia, Puey Ling ; Parakh, Sagun ; Tsao, Ming-Sound; Pham, Nhu-An; Gan, Hui K ; Cao, Diana; Burvenich, Ingrid J G; Rigopoulos, Angela; Reilly, Edward B; John, Thomas ; Scott, Andrew M |
| 164 | Oct-2020 | Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate. | Anderson, Mark G; Falls, Hugh D; Mitten, Michael J; Oleksijew, Anatol; Vaidya, Kedar S; Boghaert, Erwin R; Gao, Wenqing; Palma, Joann P; Cao, Diana; Chia, Puey Ling ; John, Thomas ; Gan, Hui K ; Scott, Andrew M ; Reilly, Edward B |
| 165 | 27-Mar-2019 | Epidermal growth factor receptor (EGFR)-targeted therapies in Mesothelioma. | Chia, Puey Ling ; Scott, Andrew M ; John, Thomas |
| 166 | 30-Jan-2019 | Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study. | Ha, Francis J; Spain, Lavinia; Dowling, Anthony; Kwan, Edmond M; Pezaro, Carmel; Day, Daphne; Chia, Puey Ling ; Tran, Ben; Pook, David; Weickhardt, Andrew J |
| 167 | Jun-2018 | The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity. | Chia, Puey Ling ; Chiang, K; Snyder, R; Dowling, A |
| 168 | 1-Apr-2018 | Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort? | John, Thomas ; Chia, Puey Ling |
| 169 | 19-Jan-2018 | Personalized chemosensitivity assays for mesothelioma- is it worth the effort? | John, Thomas ; Chia, Puey Ling |
| 170 | Aug-2017 | Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context | Itchins, M; Chia, Puey Ling ; Hayes, SA; Howell, VM; Gill, AJ; Cooper, WA; John, Thomas ; Mitchell, Paul L R ; Millward, M; Clarke, SJ; Solomon, B; Pavlakis, N |
| 171 | 12-Oct-2016 | Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma | Chia, Puey Ling ; Russell, Prudence A; Scott, Andrew M ; John, Thomas |
| 172 | Aug-2016 | Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment | Chia, Puey Ling ; Do, Hongdo; Morey, Adrienne; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas |
| 173 | Jun-2016 | Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). | Chia, Puey Ling ; John, Thomas |
| 174 | 31-May-2016 | Current and evolving methods to visualize biological data in cancer research | Chia, Puey Ling ; Gedye, Craig; Boutros, Paul C; Wheatley-Price, Paul; John, Thomas |
| 175 | Dec-2015 | Vortex Keratopathy Presumed Secondary to AZD9291. | Chia, Puey Ling ; John, Thomas |
| 176 | 20-Nov-2014 | Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. | Chia, Puey Ling ; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas |
Loading...
2
0
20
0
false